Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

Stocks were rising Tuesday and the Nasdaq Composite turned higher for the year even as uncertainty over global trade ...

Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion." ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports.

This increases the number of clinical trials led by MoonLake to ten and aligns with the plan to enroll over 3,000 patients in clinical trials with sonelokimab since the Company was founded in 2021.

Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases ...

MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than US$3 billion, the Financial Times ...